Trials / Completed

CompletedNCT06217952

Safety, Tolerability, and Pharmacokinetics of SPL84 in Healthy Volunteers

A Phase 1, Randomized, Placebo-Controlled, Double Blind Single Ascending Dose Study in Healthy Volunteers to Evaluate the Safety, Tolerability, and Pharmacokinetics of SPL84

Status: Completed
Phase: Phase 1
Study type: Interventional
Enrollment: 32 (actual)

Sponsor: SpliSense Ltd. · Industry
Sex: All
Age: 18 Years
Healthy volunteers: Accepted

Summary

This Phase 1 study evaluated the safety, tolerability, and pharmacokinetics of SPL84 single ascending doses (SAD) in healthy volunteers (HV)

Conditions

Cystic Fibrosis

Interventions

Type	Name	Description
DRUG	SPL84	SPL84 solution for nebulization
OTHER	Placebo	Placebo solution for nebulization

Timeline

Start date: 2023-02-05
Primary completion: 2023-08-06
Completion: 2023-08-06
First posted: 2024-01-23
Last updated: 2024-01-23

Locations

1 site across 1 country: Israel

Source: ClinicalTrials.gov record NCT06217952. Inclusion in this directory is not an endorsement.